Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
generic semaglutidemedical
Generic semaglutide is a widely available version of a medication originally developed to help control blood sugar levels and reduce appetite. It is used to treat conditions like type 2 diabetes and obesity, and its availability can influence the market for related drugs and healthcare costs. For investors, changes in its production or approval can impact pharmaceutical companies and the broader healthcare sector.
glp-1medical
GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.
type 2 diabetesmedical
Type 2 diabetes is a chronic condition where the body struggles to control blood sugar levels because it becomes less responsive to insulin, a hormone that helps regulate sugar in the blood. It matters to investors because it can lead to increased healthcare costs, affect workforce productivity, and influence the performance of companies in the healthcare and pharmaceutical sectors. Managing or preventing the condition has significant implications for public health and economic stability.
off-labelregulatory
Off-label describes the use of an approved drug or medical device for a purpose, patient group, dose, or method that is not listed on its official regulatory label. Think of it like using a tool for a different job than the manufacturer describes: it can expand real-world demand but also raises questions about safety, reimbursement, and legal risk. Investors watch off-label use because it can boost sales quickly but may increase regulatory scrutiny, liability, or unpredictable revenue sustainability.
Personalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical expertise, starting at $149/month
TORONTO--(BUSINESS WIRE)--
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149/month CAD.
Personalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical expertise, starting at $149/month
GLP-1 treatments have transformed obesity and metabolic health, with their significance extending well beyond weight alone. Nearly two-thirds of Canadian adults are overweight or living with obesity, but cost has remained a significant barrier to access the treatment they need. Health Canada's authorization of generic semaglutide marks a turning point, not just for Hims & Hers customers, but for the country's broader healthcare landscape. This will help create a more dynamic GLP-1 market. As more providers offer access to affordable options, prices fall across the board, expanding access for patients regardless of where they seek care.
Through Hims & Hers, eligible customers in Canada will have access to personalised care plans that may include GLP-1 options, alongside unlimited and ongoing Care Team access and evidence-informed resources built around nutrition, movement, and sleep, all designed to support sustainable, lasting health habits. All Canadian customers are connected with Canadian providers who understand the healthcare landscape they’re navigating and bring the local expertise and clinical rigour this kind of care demands.
"Generics have always played a critical role in expanding access to medicines that change lives,” said Dr. Sandy Van, Obesity Medicine Specialist and Chief Medical Officer, Hims & Hers Canada. “Today marks a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient. Every Canadian deserves access to the treatment that's right for them, regardless of what they can afford."
"Canada has a strong health system, and we are committed to helping support and strengthen it," said Austin Kouri, General Manager, Hims & Hers Canada. "Bringing generic semaglutide to market means more Canadians have a real, affordable path to treatment. When patients have options and costs come down, everyone benefits. That's exactly the kind of impact we're here to create."
Hims & Hers is committed to putting the right tools, the right providers, and the right support into the hands of Canadians who are ready to take control of their health.
Generic semaglutide is authorized for sale by Health Canada for the management of Type 2 diabetes. It may be prescribed off-label for weight management in a licensed healthcare provider's sole clinical judgment. Hims & Hers Canada Inc. does not currently offer access to treatment services for Type 2 diabetes.
About Hims & Hers Health, Inc.
Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.ca and www.forhers.ca.
